FIGURE 1: Subgroup analysis of incident CKD according to cholesterol intake. MO567 IS SARCOPENIA ASSOCIATED WITH CLINICAL OUTCOMES IN CHRONIC KIDNEY DISEASE PATIENTS? A SYSTEMATIC REVIEW AND META-ANALYSIS Heitor S. Ribeiro, 1,2* , Silvia G. R. Neri 1 , Juliana S. Oliveira 3 , Paul N. Bennett 4,5 , João L. Viana 2 and Ricardo M. Lima 1 1 Faculty of Physical Education, University of Brasília, Brasília, Brazil, 2 Research Center in Sports Sciences, Health Sciences and Human Development, CIDESD, University of Maia, Porto, Portugal, 3 Institute for Musculoskeletal Health, The University of Sydney and Sydney Local Health District, Sydney, Australia, 4 University of South Australia, Adelaide, Australia and 5 Satellite Healthcare, San Jose, USA BACKGROUND AND AIMS: Sarcopenia is a risk factor for adverse outcomes in older adults,[1], but this has yet to be confrmed in chronic kidney disease (CKD).[2] We conducted a systematic review to investigate the association between sarcopenia and its traits with mortality, hospitalization and end-stage kidney disease (ESKD) progression in CKD patients. METHOD: Five electronic databases were searched, including MEDLINE and Embase. Observational cohort studies with CKD patients were included. The sarcopenia traits assessed were low muscle strength, low muscle mass and low physical performance, as well as confrmed sarcopenia (combined low muscle mass and low strength/performance).[3] Hazard ratios (HR), risk ratios (RR), odds ratios (OR) and 95% confdence intervals (CI) were pooled using random-efect meta-analyses. RESULTS: From a total of 4922 screened studies, 50 (72 347 patients) were included in the review and 38 (59 070 patients) in the meta-analyses. Most of the included studies were in dialysis patients (n = 29, 58%). Table 1 shows that low muscle strength (15 studies; HR: 1.99; 95% CI: 1.65–2.41; I2:45%), low muscle mass (20 studies; HR: 1.51; 95% CI: 1.36–1.68; I2: 26%), low physical performance (fve studies; HR: 2.09; 95% CI: 1.68–2.59; I2: 0%) and confrmed sarcopenia (eight studies in dialysis patients; HR: 1.87; 95% CI: 1.35–2.59; I2: 40%) were associated with an increased mortality risk. On the other hand, for dialysis patients it was uncertain whether low muscle mass was associated with hospitalization (two studies; RR: 1.81; 95% CI: 0.78–4.22; I2: 59%). Further, limited ESKD progression measures prevented meta-analysis for this outcome. CONCLUSION: Low muscle strength, low muscle mass and low physical performance are associated with higher mortality in CKD patients. In dialysis patients, confrmed sarcopenia also represented higher mortality risk. Evidence to conclude associations with hospitalization and ESKD progression are currently lacking. CI, confdence interval REFERENCES 1. Xia L, Zhao R, Wan Q et al. Sarcopenia and adverse health-related outcomes: An umbrella review of meta-analyses of observational studies. Cancer Med. 2020; 9: 7964–7978 2. Sabatino A, Cuppari L, Stenvinkel P et al. Sarcopenia in chronic kidney disease: what have we learned so far? J Nephrol. 2021; 34: 1347–1372 3. Cruz-Jentoft AJ, Bahat G, Bauer J et al. Sarcopenia: revised European consensus on defnition and diagnosis. Age Ageing. 2019; 48: 16–31 MO568 THE RELATIONSHIP BETWEEN OXIDATIVE STRESS AND UNDERNUTRITION IN CKD PATIENTS Leila Azouaou 12 , Medina Arab 3 , Henni Chader 3 and Atmane Seba 4 1 Research Laboratory of Oxidative Stress, Kidney and Associated Complications, Medecine, University Algiers 1, Algiers Algeria, Algeria, 2 CHU Nafissa Hamoud, Hussein Dey, Medecine, Nephrology, Alger, Algeria, 3 University of Medecine Algiers Algeria, Alger, Algeria, 4 University of Medecine Algiers Algeria, Medecine, Nephrology, Alger, Algeria i416 Abstract Downloaded from https://academic.oup.com/ndt/article/37/Supplement_3/gfac074.013/6577643 by guest on 14 November 2022